SMT201600222B - Formulazione di anticorpi - Google Patents

Formulazione di anticorpi

Info

Publication number
SMT201600222B
SMT201600222B SM201600222T SM201600222T SMT201600222B SM T201600222 B SMT201600222 B SM T201600222B SM 201600222 T SM201600222 T SM 201600222T SM 201600222 T SM201600222 T SM 201600222T SM T201600222 B SMT201600222 B SM T201600222B
Authority
SM
San Marino
Prior art keywords
antibodies
formulation
Prior art date
Application number
SM201600222T
Other languages
English (en)
Italian (it)
Inventor
Joachim Momm
Hans-Joachim Wallny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600222(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201600222B publication Critical patent/SMT201600222B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SM201600222T 2008-12-10 2016-07-11 Formulazione di anticorpi SMT201600222B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation
PCT/EP2009/066675 WO2010066762A1 (en) 2008-12-10 2009-12-09 Antibody formulation
EP09764858.8A EP2376533B1 (en) 2008-12-10 2009-12-09 Antibody formulation

Publications (1)

Publication Number Publication Date
SMT201600222B true SMT201600222B (it) 2016-08-31

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600222T SMT201600222B (it) 2008-12-10 2016-07-11 Formulazione di anticorpi

Country Status (31)

Country Link
US (3) US20110236398A1 (cg-RX-API-DMAC7.html)
EP (4) EP2196476A1 (cg-RX-API-DMAC7.html)
JP (5) JP6143416B2 (cg-RX-API-DMAC7.html)
KR (2) KR101762966B1 (cg-RX-API-DMAC7.html)
CN (3) CN114225022A (cg-RX-API-DMAC7.html)
AU (1) AU2009324371B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0922730A2 (cg-RX-API-DMAC7.html)
CA (1) CA2745938C (cg-RX-API-DMAC7.html)
CL (1) CL2011001406A1 (cg-RX-API-DMAC7.html)
CO (1) CO6361952A2 (cg-RX-API-DMAC7.html)
CY (2) CY1117735T1 (cg-RX-API-DMAC7.html)
DK (2) DK2376533T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011192A (cg-RX-API-DMAC7.html)
ES (2) ES2579835T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20160754T1 (cg-RX-API-DMAC7.html)
HU (2) HUE028408T2 (cg-RX-API-DMAC7.html)
IL (3) IL264316B2 (cg-RX-API-DMAC7.html)
LT (1) LT3072906T (cg-RX-API-DMAC7.html)
MA (1) MA33023B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011006242A (cg-RX-API-DMAC7.html)
MY (2) MY166050A (cg-RX-API-DMAC7.html)
NZ (1) NZ592918A (cg-RX-API-DMAC7.html)
PE (1) PE20120342A1 (cg-RX-API-DMAC7.html)
PL (2) PL2376533T3 (cg-RX-API-DMAC7.html)
PT (2) PT2376533T (cg-RX-API-DMAC7.html)
RU (2) RU2563179C2 (cg-RX-API-DMAC7.html)
SI (2) SI2376533T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600222B (cg-RX-API-DMAC7.html)
TN (1) TN2011000229A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010066762A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103362B (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
EP3216462A3 (en) 2010-02-26 2017-12-20 Novo Nordisk A/S Stable antibody containing compositions
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX351706B (es) 2010-09-17 2017-10-25 Baxalta Inc Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro.
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
ES2732243T3 (es) * 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
EP3539374A1 (en) * 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN109999195A (zh) * 2012-09-20 2019-07-12 莫弗系统股份公司 类风湿关节炎的治疗
CA2891556A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CN105025925A (zh) 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
EP3188757A1 (en) * 2014-09-03 2017-07-12 Medimmune Limited Stable anti-il-4r-alpha antibody formulation
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
BR112018010211A2 (pt) 2015-12-07 2019-02-05 Merck Patent Gmbh formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
CN115998859A (zh) * 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
WO2018015897A1 (en) * 2016-07-21 2018-01-25 Novartis Ag Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
TW201904993A (zh) * 2017-06-22 2019-02-01 瑞士商諾華公司 IL-1β 結合抗體之用途
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
AU2018333106A1 (en) * 2017-09-13 2020-04-02 Novartis Ag Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
EP3768706A1 (en) * 2018-03-23 2021-01-27 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
JP7360766B2 (ja) 2018-05-17 2023-10-13 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
JP7374544B2 (ja) 2018-10-10 2023-11-07 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
NZ523080A (en) * 2000-06-29 2004-11-26 Abbott Lab Antibodies specific for interleukin-1 alpha and interleukin-2 beta and methods of making and using
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
BRPI0403964B8 (pt) * 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AR054233A1 (es) * 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2007050607A2 (en) 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
KR20090104017A (ko) * 2006-12-11 2009-10-05 에프. 호프만-라 로슈 아게 Ａ베타 항체 비경구 제제
EP2136839A4 (en) * 2007-03-22 2010-04-07 Imclone Llc STABLE ANTIBODY FORMULATIONS
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
RU2015132431A (ru) 2018-12-24
EP2376533A1 (en) 2011-10-19
RU2563179C2 (ru) 2015-09-20
PL2376533T3 (pl) 2016-09-30
EP2376533B1 (en) 2016-03-30
ECSP11011192A (es) 2011-08-31
JP7286595B2 (ja) 2023-06-05
IL212922A0 (en) 2011-07-31
TN2011000229A1 (en) 2012-12-17
RU2015132431A3 (cg-RX-API-DMAC7.html) 2018-12-24
CL2011001406A1 (es) 2012-03-30
CA2745938C (en) 2018-04-24
JP2020203889A (ja) 2020-12-24
CN102245639A (zh) 2011-11-16
EP3792282A1 (en) 2021-03-17
EP3072906B1 (en) 2021-09-08
MA33023B1 (fr) 2012-02-01
JP6143416B2 (ja) 2017-06-07
ES2900624T3 (es) 2022-03-17
BRPI0922730A2 (pt) 2018-11-06
CN104399076B (zh) 2021-09-14
KR101762966B1 (ko) 2017-07-31
CN102245639B (zh) 2014-12-24
SI3072906T1 (sl) 2022-01-31
AU2009324371B2 (en) 2013-10-10
RU2745601C2 (ru) 2021-03-29
EP3072906A1 (en) 2016-09-28
KR20120009421A (ko) 2012-01-31
IL276622A (en) 2020-09-30
HRP20160754T1 (hr) 2016-08-12
PT2376533T (pt) 2016-07-13
JP2012511540A (ja) 2012-05-24
CA2745938A1 (en) 2010-06-17
PL3072906T3 (pl) 2022-01-24
EP2196476A1 (en) 2010-06-16
CY1117735T1 (el) 2017-05-17
MX2011006242A (es) 2011-06-24
JP2015231997A (ja) 2015-12-24
MY166050A (en) 2018-05-22
ES2579835T3 (es) 2016-08-17
US20120315285A1 (en) 2012-12-13
JP2023109938A (ja) 2023-08-08
IL212922B (en) 2019-02-28
HUE056626T2 (hu) 2022-02-28
JP2018168158A (ja) 2018-11-01
AU2009324371A1 (en) 2011-06-23
DK3072906T3 (da) 2021-12-13
RU2011127913A (ru) 2013-01-20
US20200384108A1 (en) 2020-12-10
SI2376533T1 (sl) 2016-07-29
LT3072906T (lt) 2021-12-27
US20110236398A1 (en) 2011-09-29
PE20120342A1 (es) 2012-04-24
CO6361952A2 (es) 2012-01-20
CN114225022A (zh) 2022-03-25
KR20170044211A (ko) 2017-04-24
DK2376533T3 (en) 2016-06-27
HUE028408T2 (en) 2016-12-28
IL264316A (en) 2019-02-28
HK1159130A1 (zh) 2012-07-27
IL264316B2 (en) 2024-01-01
ZA201103362B (en) 2012-01-25
CN104399076A (zh) 2015-03-11
IL264316B1 (en) 2023-09-01
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
HRP20211899T1 (hr) 2022-03-04
CY1124844T1 (el) 2022-11-25
PT3072906T (pt) 2021-12-14
WO2010066762A1 (en) 2010-06-17
US8623367B2 (en) 2014-01-07

Similar Documents

Publication Publication Date Title
SMT201600222B (it) Formulazione di anticorpi
EP2358392A4 (en) ANTIBODY FORMULATION
DK2459167T3 (da) SUBKUTAN ANTI-HER2-antistofformulering
BRPI1006519A2 (pt) formulação de anticorpos
DK2234600T3 (da) Antistofformulering
BRPI0917888A2 (pt) Formulação de anticorpo líquida estável
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
EP2262831A4 (en) ANTI-properdin antibody
PT2170388T (pt) Formulações de anticorpos anti-cd20
BRPI0912026A2 (pt) formulação homeopática
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
EP2207803A4 (en) Cd9-specific human antibodies
BRPI0918419A2 (pt) nova formulação anticorpo
BRPI1009465A2 (pt) Formulação
BRPI0909633A2 (pt) anticorpos anti-tyrp1
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
EP2350385A4 (en) Forming section
EP2426149A4 (en) ANTI-CADHERIN ANTIBODY
BRPI0912769A2 (pt) anticorpos anti-pirb
ITTO20110268A1 (it) Composizione di maquillage.
CU23884B1 (es) Derivados de dibenzotiazepina